|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Endoscopic radiofrequency ablation for malignant biliary obstruction: a nationwide retrospective study of 84 consecutive applications显示文摘 | Werner Dolak Florian Schreiber Hubert Schwaighofer Michael Gschwantler Wolfgang Plieschnegger Alexander Ziachehabi Andreas Mayer Ludwig Kramer Andreas Kopecky Christiane Schrutka-K?lbl Gernot Wolkersd?rfer Christian Madl Frieder Berr Michael Trauner Andre | 2014 | Surgical Endoscopy2014，，3： | 3 |
| 2 | Percutaneous Left Atrial Appendage Transcatheter Occlusion to Prevent Stroke in High-Risk Patients With Atrial Fibrillation: Early Clinical Experience显示文摘 | Horst Sievert Michael D. Lesh Thomas Trepels Heyder Omran Antonio Bartorelli Paola Della Bella Toshiko Nakai Mark Reisman Carlo DiMario Peter Block Paul Kramer Dirk Fleschenberg Ulrike Krumsdorf Detlef Scherer | 2002 | Circulation: Journal of the American Heart Association2002，，16： | 2 |
| 3 | STAT3 inhibition sensitizes colorectal cancer to chemoradiotherapy in vitro and in vivo显示文摘 | Melanie Spitzner Birte Roesler Christian Bielfeld Georg Emons Jochen Gaedcke Hendrik A. Wolff Margret Rave‐Fr?nk Frank Kramer Tim Beissbarth Julia Kitz Jürgen Wienands B. Michael Ghadimi Reinhard Ebner Thomas Ried Marian Grade | 2014 | Int J Cancer2014，，4： | 2 |
| 4 | Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol显示文摘 | Thomas Reiberger Gregor Ulbrich Arnulf Ferlitsch Berit Anna Payer Philipp Schwabl Matthias Pinter Birgit B Heinisch Michael Trauner Ludwig Kramer Markus Peck-Radosavljevic | 2013 | Gut2013，，11： | 2 |
| 5 | Identification of a microRNA expression signature for chemoradiosensitivity of colorectal cancer cells, involving miRNAs-320a, -224, -132 and let7g显示文摘 | Junius Salendo Melanie Spitzner Frank Kramer Xin Zhang Peter Jo Hendrik A. Wolff Julia Kitz Silke Kaulfu? Tim Bei?barth Matthias Dobbelstein Michael Ghadimi Marian Grade Jochen Gaedcke | 2013 | Radiotherapy and Oncology2013，，： | 2 |
| 6 | Identification of a microRNA expression signature for chemoradiosensitivity of colorectal cancer cells, involving miRNAs-320a, -224, -132 and let7g<!-- MicroRNA chemoradiosensitivity signature -->显示文摘 | Junius Salendo Melanie Spitzner Frank Kramer Xin Zhang Peter Jo Hendrik A. Wolff Julia Kitz Silke Kaulfu? Tim Bei?barth Matthias Dobbelstein Michael Ghadimi Marian Grade Jochen Gaedcke | 2013 | Radiotherapy and Oncology2013，，： | 2 |
| 7 | ACCF/ACR/AHA/NASCI/SCMR 2010 Expert Consensus Document on Cardiovascular Magnetic Resonance显示文摘 | W. Gregory Hundley David A. Bluemke J. Paul Finn Scott D. Flamm Mark A. Fogel Matthias G. Friedrich Vincent B. Ho Michael Jerosch-Herold Christopher M. Kramer Warren J. Manning Manesh Patel Gerald M. Pohost Arthur E. Stillman Richard D. White Pamela K. Wo | 2010 | Journal of the American College of Cardiology2010，，23： | 1 |
| 8 | Could inflammation be a key com- ponent in the progession of benign pmstalic hyperplasia 显示文摘 | Kramer Gero Marberger Michael | 2006 | CUlT Opi- nin Uro12006，16，： | 1 |
| 9 | Clinical efficacy of cardiac resynchronization therapy using left ventricular pacing in heart failure patients stratified by severity of ventricular conduction delay显示文摘 | Angelo Auricchio Christoph Stellbrink Christian Butter Stefan Sack Jürgen Vogt Anand Ramdat Misier Dirk B?cker Michael Block Johannes H Kirkels Andrew Kramer Etienne Huvelle | 2003 | Journal of the American College of Cardiology2003，，12： | 1 |
| 10 | Re-duced early Holocene moisture availability in the Bayan HarMountains,northeastern Tibetan Plateau,inferred from amulti-proxy lake record显示文摘 | Steffen Mischke Michael Kramer Chengjun Zhang | 2008 | Palaeogeography Palaeoclimatolo-gy Palaeoecology2008，267，： | 1 |
| 11 | The Competitive Advantage of Corporate Philanthropy 显示文摘 | MichaelE Porter MarkR Kramer | 2002 | Harvard Business Review2002，80，68： | 1 |
| 12 | Endogenous fungal endophthalmitis:risk factors,clinical course,and visual outcome in 13 patients显示文摘AIM:To analyze the risk factors,ophthalmological features,treatment modalities and their effect on the visual outcome in patients with endogenous fungal endophthalmitis(EFE).METHODS:Data retrieved from the medical files included age at presentation to the uveitis clinic,gender,ocular symptoms and their duration before presentation,history of fever,eye affected,anatomical diagnosis and laboratory evidence of fungal infection.Medical therapy recorded included systemic antifungal therapy and its duration,use of intravitreal antifungal agents and use of oral/intravitreal steroids.Surgical procedures and the data of ophthalmologic examination at presentation and at last follow-up were also collected.RESULTS:Included were 13 patients(20 eyes,mean age 58 y).Ten patients presented after gastrointestinal or urological interventions and two presented after organ transplantation.In one patient,there was no history of previous intervention.Diagnostic vitrectomy was performed in 16 eyes(80%)and vitreous cultures were positive in 10 of the vitrectomized eyes(62.5%).In only 4 patients(31%),blood cultures were positive.All patients received systemic antifungal therapy.Sixteen eyes(80%)received intravitreal antifungal agent with voriconazole being the most commonly used.Visual acuity(VA)improved from 0.9±0.9 at initial exam to 0.5±0.8 logMAR at last followup(P=0.03).A trend of greater visual improvement was noted in favor of eyes treated with oral steroids(±intravitreal dexamethasone)than eyes that were not treated with steroids.The most common complication was maculopathy.Twelve eyes(60%)showed no ocular complications.CONCLUSION:High index of suspicion in patients with inciting risk factors is essential because of the low yield of blood cultures and the good general condition of patients at presentation.Visual prognosis is improved with the prompt institution of systemic and intravitreal pharmacotherapy and the immediate surgical intervention.Oral±local steroids could be considered in cases of prolonged or marked inflammatory responses in order to hasten control of inflammation and limit ocular complications. | Jamel Corredores Itzhak Hemo Tareq Jaouni Zohar Habot-Wilner Michal Kramer Shiri Shulman Haneen Jabaly-Habib Ala'a Al-Talbishi Michael Halpert Edward Averbukh Jaime Levy Iris Deitch-Harel Radgonde Amer | 2021 | International Journal of Ophthalmology(English edition)2021，14，1： | 1 |
| 13 | The Association Between Low Birth Weight and Type 2 Diabetes: Contribution of Genetic Factors显示文摘 | Stefan Johansson Anastasia Iliadou Niklas Bergvall Ulf dé Fairé Michael S. Kramer Yudi Pawitan Nancy L. Pedersen Mikael Norman Paul Lichtenstein Sven Cnattingius | 2008 | Epidemiology2008，，5： | 1 |
| 14 | “Strategy and Society:The Link Between Competitive Advantage and Corporate Social Responsibility显示文摘 | Porter Michael Mark Kramer | | 0，，： | 1 |
| 15 | The Controversial Relationship Between Benign Prostatic Hyperplasia and Prostate Cancer: The Role of Inflammation显示文摘 | Cosimo De Nunzio Gero Kramer Michael Marberger Rodolfo Montironi William Nelson Fritz Schr?der Alessandro Sciarra Andrea Tubaro | 2011 | European Urology2011，，1： | 1 |
| 16 | 'Creating Shared Value显示文摘 | Porter Michael E Mark R. Kramer | | 0，，1： | 1 |
| 17 | ACCF/ACR/AHA/NASCI/SCMR 2010 Expert Consensus Document on Cardiovascular Magnetic Resonance: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents显示文摘 | W. Gregory. Hundley David A. Bluemke J. Paul Finn Scott D. Flamm Mark A. Fogel Matthias G. Friedrich Vincent B. Ho Michael Jerosch-Herold Christopher M. Kramer Warren J. Manning Manesh Patel Gerald M. Pohost Arthur E. Stillman Richard D. White Pamela K. W | 2010 | Circulation2010，，22： | 1 |
| 18 | Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol显示文摘 | Thomas Reiberger Gregor Ulbrich Arnulf Ferlitsch Berit Anna Payer Philipp Schwabl Matthias Pinter Birgit B Heinisch Michael Trauner Ludwig Kramer Markus Peck-Radosavljevic | 2013 | Gut2013，，11： | 1 |
| 19 | Outcomes following liver transplantation in intensive care unit patients显示文摘AIM:To determine feasibility of liver transplantation in patients from the intensive care unit (ICU) by estimating graft and patient survival.METHODS:This single center retrospective study included 39 patients who had their first liver transplant directly from the intensive care unit and 927 non-ICU patients who were transplanted from hospital ward or home between January 2005 and December 2010.RESULTS:In comparison to non-ICU patients,ICU patients had a higher model for end-stage liver disease (MELD) at transplant (median:37 vs 20,P < 0.001).Fourteen out of 39 patients (36%) required vasopressor support immediately prior to liver transplantation (LT) with 6 patients (15%) requiring both vasopressin and norepinephrine.Sixteen ICU patients (41%) were ventilator dependent immediately prior to LT with 9 patients undergoing percutaneous tracheostomy prior to transplantation.Twenty-five ICU patients (64%) required dialysis preoperatively.At 1,3 and 5 years after LT,graft survival was 76%,68% and 62% in ICU patients vs 90%,81% and 75% in non-ICU patients.Patient survival at 1,3 and 5 years after LT was 78%,70% and 65% in ICU patients vs 94%,85% and 79% in non-ICU patients.When formally comparing graft survival and patient survival between ICU and nonICU patients using Cox proportional hazards regression models,both graft survival [relative risk (RR):1.94,95%CI:1.09-3.48,P=0.026] and patient survival (RR:2.32,95%CI:1.26-4.27,P=0.007) were lower in ICU patients vs non-ICU patients in single variable analysis.These findings were consistent in multivariable analysis.Although not statistically significant,graft survival was worse in both patients with cryptogenic cirrhosis (RR:3.29,P=0.056) and patients who received donor after cardiac death (DCD) grafts (RR:3.38,P=0.060).These findings reached statistical significance when considering patient survival,which was worse for patients with cryptogenic cirrhosis (RR:3.97,P=0.031) and patients who were transplanted with DCD livers (RR:4.19,P=0.033).Graft survival and patient survival were not significantly worse for patients on mechanical ventilation (RR:0.91,P=0.88 in graft loss;RR:0.69,P=0.56 in death) or patients on vasopressors (RR:1.06,P=0.93 in graft loss;RR:1.24,P=0.74 in death) immediately prior to LT.Trends toward lower graft survival and patient survival were observed for patients on dialysis immediately before LT,however these findings did not approach statistical significance (RR:1.70,P=0.43 in graft loss;RR:1.46,P=0.58 in death).CONCLUSION:Although ICU patients when compared to non-ICU patients have lower survivals,outcomes are still acceptable.Pre-transplant ventilation,hemodialysis,and vasopressors were not associated with adverse outcomes. | Lena Sibulesky Michael G Heckman C Burcin Taner Juan M Canabal Nancy N Diehl Dana K Perry Darren L Willingham Surakit Pungpapong Barry G Rosser David J Kramer Justin H Nguyen | 2013 | World Journal of Hepatology2013，5，1： | 1 |
| 20 | The competitive advantage of corporate philanthropy 显示文摘 | MICHAEL E PORTER MARK R KRAMER | 2002 | Harvard Business Review2002，，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员